Cadence Sues Exela, Paddock To Block Generic Ofirmev

Law360, New York (August 19, 2011, 6:46 PM EDT) -- Cadence Pharmaceuticals Inc. launched a patent infringement suit against generics makers Paddock Laboratories Inc. and Exela Pharma Sciences LLC in Delaware federal court on Thursday, seeking to block a generic version of Ofirmev, an injectable form of the pain reliever acetaminophen.

Cadence and SCR Pharmatop claim that Paddock and Exela's abbreviated new drug applications infringe patents in seeking permission to manufacture injectable acetaminophen. Ofirmev was approved by the U.S. Food and Drug Administration on Nov. 2, 2010, as a treatment for mild to moderate pain and...
To view the full article, register now.